NovaBridge Biosciences appointed Dr. Srishti Gupta as Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu stepped down as CEO to pursue other opportunities but will support the company in an advisory capacity during the transition. NovaBridge is a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need.
